A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (ESSENCE)
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Tezepelumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Acronyms ESSENCE
- Sponsors AstraZeneca
- 17 Jan 2025 Planned End Date changed from 26 Jan 2027 to 4 Feb 2027.
- 17 Jan 2025 Planned primary completion date changed from 26 Jan 2027 to 4 Feb 2027.
- 20 Dec 2024 Planned End Date changed from 29 Jan 2027 to 26 Jan 2027.